Intravitreal Corticosteroids in the Management of Diabetic Macular Edema

Stephen G. Schwartz; Harry W. Flynn; Ingrid U. Scott

doi:10.1007/s40135-013-0015-3

Intravitreal Corticosteroids in the Management of Diabetic Macular Edema

Stephen G. Schwartz
, Harry W. Flynn
, Ingrid U. Scott

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Diabetic macular edema (DME) remains an important cause of visual loss worldwide. Corticosteroids have a role in the treatment of some patients with advanced or recurrent DME. The best studied steroids for this indication are triamcinolone acetonide, dexamethasone, and fluocinolone acetonide. All steroids are associated with risks of cataract and intraocular pressure elevation. In addition, intravitreal injection of any medication is associated with such risks as infectious endophthalmitis, which has led to the investigation of various extended-release steroid implants. At this time, no steroid is approved by the United States Food and Drug Administration for the treatment of DME.

Original language	English (US)
Pages (from-to)	144-149
Number of pages	6
Journal	Current Ophthalmology Reports
Volume	1
Issue number	3
DOIs	https://doi.org/10.1007/s40135-013-0015-3
State	Published - Sep 1 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Ophthalmology

Access to Document

10.1007/s40135-013-0015-3

Cite this

@article{d350fd90bd794be99df0376283afadf1,

title = "Intravitreal Corticosteroids in the Management of Diabetic Macular Edema",

abstract = "Diabetic macular edema (DME) remains an important cause of visual loss worldwide. Corticosteroids have a role in the treatment of some patients with advanced or recurrent DME. The best studied steroids for this indication are triamcinolone acetonide, dexamethasone, and fluocinolone acetonide. All steroids are associated with risks of cataract and intraocular pressure elevation. In addition, intravitreal injection of any medication is associated with such risks as infectious endophthalmitis, which has led to the investigation of various extended-release steroid implants. At this time, no steroid is approved by the United States Food and Drug Administration for the treatment of DME.",

author = "Schwartz, \{Stephen G.\} and Flynn, \{Harry W.\} and Scott, \{Ingrid U.\}",

note = "Funding Information: This study was partially supported by NIH Center Core Grant P30EY014801, an Unrestricted Grant from Research to Prevent Blindness (New York, NY), and the Department of Defense (DOD Grant \#W81XWH-09-1-0675). Publisher Copyright: {\textcopyright} 2013, Springer Science + Business Media New York.",

year = "2013",

month = sep,

day = "1",

doi = "10.1007/s40135-013-0015-3",

language = "English (US)",

volume = "1",

pages = "144--149",

journal = "Current Ophthalmology Reports",

issn = "2167-4868",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Intravitreal Corticosteroids in the Management of Diabetic Macular Edema

AU - Schwartz, Stephen G.

AU - Flynn, Harry W.

AU - Scott, Ingrid U.

N1 - Funding Information: This study was partially supported by NIH Center Core Grant P30EY014801, an Unrestricted Grant from Research to Prevent Blindness (New York, NY), and the Department of Defense (DOD Grant #W81XWH-09-1-0675). Publisher Copyright: © 2013, Springer Science + Business Media New York.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Diabetic macular edema (DME) remains an important cause of visual loss worldwide. Corticosteroids have a role in the treatment of some patients with advanced or recurrent DME. The best studied steroids for this indication are triamcinolone acetonide, dexamethasone, and fluocinolone acetonide. All steroids are associated with risks of cataract and intraocular pressure elevation. In addition, intravitreal injection of any medication is associated with such risks as infectious endophthalmitis, which has led to the investigation of various extended-release steroid implants. At this time, no steroid is approved by the United States Food and Drug Administration for the treatment of DME.

AB - Diabetic macular edema (DME) remains an important cause of visual loss worldwide. Corticosteroids have a role in the treatment of some patients with advanced or recurrent DME. The best studied steroids for this indication are triamcinolone acetonide, dexamethasone, and fluocinolone acetonide. All steroids are associated with risks of cataract and intraocular pressure elevation. In addition, intravitreal injection of any medication is associated with such risks as infectious endophthalmitis, which has led to the investigation of various extended-release steroid implants. At this time, no steroid is approved by the United States Food and Drug Administration for the treatment of DME.

UR - https://www.scopus.com/pages/publications/84906806780

UR - https://www.scopus.com/pages/publications/84906806780#tab=citedBy

U2 - 10.1007/s40135-013-0015-3

DO - 10.1007/s40135-013-0015-3

M3 - Article

AN - SCOPUS:84906806780

SN - 2167-4868

VL - 1

SP - 144

EP - 149

JO - Current Ophthalmology Reports

JF - Current Ophthalmology Reports

IS - 3

ER -

Intravitreal Corticosteroids in the Management of Diabetic Macular Edema

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this